Identification of fucosylated Fetuin-A as a potential biomarker for cholangiocarcinoma.

Autor: Betesh L; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA., Comunale MA; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA., Wang M; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA., Liang H; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA., Hafner J; The Baruch Blumberg Institute, Doylestown, PA, USA., Karabudak A; The Baruch Blumberg Institute, Doylestown, PA, USA., Giama NH; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA., Moser CD; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA., Miyoshi E; Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Japan., Roberts LR; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA., Block TM; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA., Mehta A; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA.
Jazyk: angličtina
Zdroj: Proteomics. Clinical applications [Proteomics Clin Appl] 2017 Sep; Vol. 11 (9-10). Date of Electronic Publication: 2017 Jul 10.
DOI: 10.1002/prca.201600141
Abstrakt: Purpose: Cholangiocarcinoma (CCA) is a malignancy of the bile ducts. The purpose of this discovery study was to identify effective serum markers for surveillance of cholangiocarcinoma.
Experimental Design: Using a glycomic method, patients with CCA were determined to have increased levels of alpha-1,3 and alpha-1,6 linked fucosylated glycan. Proteomic analysis of the serum fucosylated proteome identified proteins such as alpha-2-macroglobulin, kininogen, hemopexin, fetuin-A, alpha-1 anti-trypsin, and ceruloplasmin as being hyperfucosylated in HCC. The levels of these glycoproteins in 109 patients with CCA, primary sclerosing cholangitis (PSC), and control patients were compared to the performance of CA-19-9, the current "gold standard" assay for cholangiocarcinoma.
Results: Fucosylated Fetuin-A (fc-Fetuin-A) had the best ability to differentiate CCA from PSC, with an AUROC of 0.812 or 0.8665 at differentiating CCA from those with PSC or other liver disease. CA-19-9 had poor ability to differentiate PSC from cholangiocarcinoma (AUROC of 0.625).
Conclusion and Clinical Relevance: Using glycomic and proteomic methods we identified a set of proteins that contain altered glycan in the sera of those with CCA. One of these proteins, fucosylated Fetuin-A may have value in the surveillance of people at risk for the development of cholangiocarcinoma.
(© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
Databáze: MEDLINE
Externí odkaz: